11/21
10:30 am
arvn
Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVN
Medium
Report
Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ARVN
11/21
10:00 am
arvn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out
11/21
05:12 am
arvn
HPK1 Inhibitors Pipeline Market Research Report 2024: Therapeutics Assessment of 10+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
Medium
Report
HPK1 Inhibitors Pipeline Market Research Report 2024: Therapeutics Assessment of 10+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]
11/20
12:15 pm
arvn
Arvinas, Inc. (ARVN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
Low
Report
Arvinas, Inc. (ARVN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
11/20
12:00 pm
arvn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
11/20
10:00 am
arvn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out
Medium
Report
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out
11/20
09:31 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at BMO Capital Markets from $90.00 to $88.00. They now have an "outperform" rating on the stock.
Medium
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at BMO Capital Markets from $90.00 to $88.00. They now have an "outperform" rating on the stock.
11/19
03:45 pm
arvn
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc. - ARVN
11/18
08:50 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) is now covered by analysts at Stephens. They set an "overweight" rating and a $55.00 price target on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) is now covered by analysts at Stephens. They set an "overweight" rating and a $55.00 price target on the stock.
11/4
07:00 am
arvn
Arvinas to Participate in Upcoming Investor Conferences
Low
Report
Arvinas to Participate in Upcoming Investor Conferences
11/1
10:08 am
arvn
Arvinas Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
Arvinas Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
10/31
10:42 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
10/31
09:32 am
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $50.00 to $40.00. They now have an "outperform" rating on the stock.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $50.00 to $40.00. They now have an "outperform" rating on the stock.
10/30
07:00 am
arvn
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Low
Report
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/25
07:35 am
arvn
We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely [Yahoo! Finance]
Medium
Report
We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely [Yahoo! Finance]
10/23
12:17 pm
arvn
PROTAC Targeted Protein Degraders Market Clinical Trials Insight to 2027 - Emerging PROTAC Therapeutics Set to Revolutionize Targeted Protein Degradation in Clinical Trials [Yahoo! Finance]
Low
Report
PROTAC Targeted Protein Degraders Market Clinical Trials Insight to 2027 - Emerging PROTAC Therapeutics Set to Revolutionize Targeted Protein Degradation in Clinical Trials [Yahoo! Finance]
10/22
04:05 pm
arvn
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
Low
Report
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
10/21
07:00 am
arvn
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
Medium
Report
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
10/16
05:14 pm
arvn
Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause [Seeking Alpha]
Low
Report
Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause [Seeking Alpha]
10/11
06:47 am
arvn
Proteolysis Targeting Chimeras PROTAC Therapy For Lung Cancer [Yahoo! Finance]
Medium
Report
Proteolysis Targeting Chimeras PROTAC Therapy For Lung Cancer [Yahoo! Finance]
9/14
09:36 am
arvn
Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago [Yahoo! Finance]
Low
Report
Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago [Yahoo! Finance]
9/9
01:03 pm
arvn
Arvinas, Inc. (NASDAQ: ARVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Arvinas, Inc. (NASDAQ: ARVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
8/29
07:00 am
arvn
Arvinas to Participate in Upcoming Investor Conferences
Low
Report
Arvinas to Participate in Upcoming Investor Conferences